Apparently this PR from the company has been misse
Post# of 295
(Total Views: 227)
Posted On: 01/02/2020 1:07:09 PM
Apparently this PR from the company has been missed so I will repost it and the answer to the question is well within this PR:
Quote:
BALTIMORE, MD, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Greater Cannabis Company (OTCQB: GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems and cannabinoids products is proud to announce that is has advanced its cannabidiol research study with researchers from Hadassah Hebrew University Hospital and Research Center.
The first cooperative effort involves studying different formulations of cannabidiol (CBD) using Greater Cannabis’ innovative delivery platform, which has been successful in achieving 40-50% bioavailability using different active pharmaceutical ingredients (APIs). The study will help further substantiate the significance of the eluting transmucosal patch (ETP) platform, and advance a number of ongoing discussions the Company has with pharmaceutical and cannabis companies.
The researchers involved in the study stem from the Hebrew University Cannabis Research Center, the home of Dr. Rephael Mechoulam, “father of cannabis”, and other renowned researchers. They have decades of experience in cannabis research, and have published hundreds of publications on the subject in leading journals. “We have identified and partnered with the most experienced cannabis researchers in the World who were studying the effects of CBD years before it became a popular product”, said Aitan Zacharin, CEO of the Greater Cannabis Company. “With the knowledge we have that our delivery platform is an incredibly effective way of administering cannabinoids, we knew that we needed the top teams in the industry to work on developing and executing our study protocols. With this data we intend to further substantiate our claims, and advance the clinical applications of our technology, while continuing in parallel paths with the commercialization of our products.”
Quote:
BALTIMORE, MD, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Greater Cannabis Company (OTCQB: GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems and cannabinoids products is proud to announce that is has advanced its cannabidiol research study with researchers from Hadassah Hebrew University Hospital and Research Center.
The first cooperative effort involves studying different formulations of cannabidiol (CBD) using Greater Cannabis’ innovative delivery platform, which has been successful in achieving 40-50% bioavailability using different active pharmaceutical ingredients (APIs). The study will help further substantiate the significance of the eluting transmucosal patch (ETP) platform, and advance a number of ongoing discussions the Company has with pharmaceutical and cannabis companies.
The researchers involved in the study stem from the Hebrew University Cannabis Research Center, the home of Dr. Rephael Mechoulam, “father of cannabis”, and other renowned researchers. They have decades of experience in cannabis research, and have published hundreds of publications on the subject in leading journals. “We have identified and partnered with the most experienced cannabis researchers in the World who were studying the effects of CBD years before it became a popular product”, said Aitan Zacharin, CEO of the Greater Cannabis Company. “With the knowledge we have that our delivery platform is an incredibly effective way of administering cannabinoids, we knew that we needed the top teams in the industry to work on developing and executing our study protocols. With this data we intend to further substantiate our claims, and advance the clinical applications of our technology, while continuing in parallel paths with the commercialization of our products.”
(0)
(0)